Accuray Incorporated — FY2017 Form 10-K
Period clarification: The supplied filing is the annual report for the fiscal year ended June 30, 2017, not a filing limited to 2016 Q4. It includes unaudited quarterly data for FY2017 and FY2016.
Business context and reporting period
Accuray develops, manufactures, sells, and services radiation oncology systems, principally CyberKnife and TomoTherapy, including the next-generation Radixact platform, and related treatment-planning and data-management software. FY2017 financial statements are audited; the auditor issued an unqualified opinion, and management and the auditor reported effective internal control over financial reporting.
Key financial metrics
| Metric | FY2017 | FY2016 |
|---|---|---|
| Net revenue | $383.4 million | $398.8 million |
| Product revenue | $179.6 million | $193.3 million |
| Service revenue | $203.8 million | $205.5 million |
| Gross profit / margin | $141.3 million / 37% | $158.7 million / 40% |
| Operating loss | $9.8 million | $4.9 million |
| Net loss | $29.6 million; $0.36 per share | $25.5 million; $0.32 per share |
| Cash from operating activities | $(0.4) million | $30.9 million |
| Cash and cash equivalents | $72.1 million | $119.8 million |
| Short-term investments | $23.9 million | $47.2 million |
| Working capital | $24.5 million | $151.5 million |
Product gross margin fell to 37% from 44%; service gross margin edged up to 37% from 36%. Operating expenses were $151.2 million, down from $163.6 million. Other expense, principally interest, was $18.7 million. Total liabilities were $359.9 million, including $113.0 million of short-term debt and $51.5 million of long-term debt; stockholders’ equity was $46.5 million. The filing reports no FY2017 operating cash generation in practical terms, and cash, cash equivalents and investments together totaled $96.0 million at year-end, excluding restricted cash.
FY2017 Q4 revenue was $112.1 million, gross profit $43.2 million, and net loss $5.3 million, compared with revenue of $95.0 million, gross profit of $37.3 million, and net loss of $7.2 million in FY2016 Q4.
Changes versus the prior comparable period
- Revenue declined 4% year over year. Product revenue fell 7%, chiefly because fewer CyberKnife systems were recognized as revenue, average system revenue declined, and distributor-channel conversion was slower. Service revenue decreased 1%.
- Gross margin declined three percentage points. Product margin contracted seven points, attributed mainly to higher system manufacturing and overhead costs; service margin improved one point.
- Net loss widened by $4.1 million and operating loss widened by $4.9 million, despite lower R&D and general and administrative spending.
- Operating cash flow fell from $30.9 million provided to $0.4 million used. Higher receivables—partly associated with longer customer payment terms—and lower deferred revenue and customer advances weighed on cash flow.
- Product backlog increased to $452.8 million from $405.9 million. Net orders rose modestly to $226.6 million; FY2017 gross orders were $298.3 million and cancellations were $13.8 million. Backlog is not a GAAP measure and may be reduced by cancellations, age-outs, and currency movements.
Outlook, management commentary, risks, and unusual items
- Management expects FY2018 R&D expense to exceed FY2017, reflecting planned development investment; selling and marketing expense to be slightly higher due to launches and added headcount; and G&A to be relatively flat. The filing gives no numeric revenue, earnings, or margin guidance.
- Management stated that available cash, cash equivalents, investments, and expected cash flows should fund operations for at least 12 months. This outlook is subject to execution, collection, and market risks.
- In June 2017, Accuray entered a $52 million asset-backed revolving facility, with possible increases to $85 million subject to lender approval and borrowing-base availability. It is secured by substantially all borrower assets, carries interest at adjusted 90-day LIBOR (minimum 1%) plus 4.50%, and includes covenants. The prior secured term loan was repaid in June 2017.
- After year-end, on August 7, 2017, the company issued $85 million of 3.75% convertible notes through an exchange and cash offering; approximately $40 million principal of the existing 3.50% notes remained outstanding afterward. These subsequent transactions are not included in June 30, 2017 balance-sheet debt amounts.
- Key risks include extended sales and installation cycles, order cancellations and aging, dependence on reimbursement and regulatory approvals, intense competition, single-source component suppliers, international and foreign-exchange exposure, customer financing and collection risk, and product liability or recall exposure. Two CyberKnife recalls were initiated in FY2017 and closed with the FDA; the filing reports no serious adverse health consequences and says costs were not material.
- Management reported no probable and estimable losses for current legal proceedings at year-end, while cautioning that litigation outcomes are uncertain. The company had an accumulated deficit of $450.4 million and a full valuation allowance against domestic deferred tax assets.
- Accuray adopted new restricted-cash cash-flow presentation guidance in FY2017 without significant impact. It planned to adopt the new revenue-recognition standard in FY2019; its preliminary assessment anticipated some product revenue acceleration on delivery and deferral of installation revenue until performed.
Important facts for investors to verify
- Whether FY2018 sales, system installations, product mix, and backlog conversion can recover after the FY2017 revenue decline and margin compression.
- Cash conversion and receivable quality, including the effect of extended payment terms and customer concentration: two customers represented 30% of year-end net accounts receivable.
- Debt repayment and refinancing capacity, revolver borrowing-base availability, covenant compliance, and potential cash or share settlement of convertible notes.
- Whether Radixact and other launches gain commercial traction, and whether supplier, regulatory, reimbursement, and recall risks affect delivery or adoption.
- Potential earnings and balance-sheet effects of the FY2019 revenue-recognition transition and continued losses on the realization of tax attributes.